Phase 2b/3 Trial Shows Efficacy of Filgotinib for Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis (UC)

RCT (n=1,348) found a significantly higher proportion of biologic-naïve (26.1% vs. 15.3%, p=0.0157) and biologic-experienced patients (11.5% vs. 4.2%, p=0.0103) treated with filgotinib 200mg achieved clinical remission at Week 10 vs. placebo.

SPS commentary:

Results of the study also demonstrated that filgotinib patients maintained remission through Week 58, and significantly more patients achieved six-month corticosteroid-free remission. Filgotinib is an oral JAK1 preferential inhibitor, currently only licensed in the UK and EU for treatment of rheumatoid arthritis.

Biospace Inc.